Bluebird bio, Inc. Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (66)

View All

Latest Posts

About This Stock More About This Stock
Biotech (Top 30 Weights) 2019 Earnings Estimates Up 8.58% In Last 2 Months
Article By: T.J. Hayes
Monday, September 9, 2019 7:36 PM EDT
The cumulative earnings power of these 30 stocks was revised UP by 8.58% in the past 60 days.
In this article: ALNY, ALXN, BMRN, CBPO, ILMN, INCY, JAZZ, REGN, SGEN, AMGN, BIIB, CELG, EXEL, GILD, HZNP, MYL, NBIX, TECH, VRTX, AMRN, SAGE, GWPH, SRPT, BLUE, NVCR, IONS, BGNE, PRAH, SYNH, IBB
Read
Biopharma Stocks Rally And Gene Therapy Stocks Are Still Hot
Article By: Rod Raynovich
Friday, March 22, 2019 7:17 AM EDT
Mid-Cap biotech stocks ran up today along with a broad market rally in tech stocks with the NAZ up 1.42% and the XLK​ up 2.51%.
In this article: NAZ, RHHBY, BLUE, BIIB, XLK, ACIU
Read
Small Cap Biotechs Lead The Market In 2019 Up 20% YTD
Article By: Rod Raynovich
Thursday, February 28, 2019 12:20 PM EDT
Gene Therapy stocks soar on Spark (ONCE) Deal: BLUE, CRSP, RARE; and XBI up 4.2%.
In this article: ONCE, RARE, DHR, GE, XBI, BLUE, CRSP, IWM, XLV, MRK, RHHBY, BMY, CELG, LOXO, LLY, GNMK, AMRN, TDOC
Read
5 Best Biotech Bets Likely To Outperform Estimates In Q4
Article By: Zacks Investment Research
Wednesday, January 23, 2019 2:06 PM EDT
There are multiple drug/biotech companies poised to beat on fourth-quarter earnings.
In this article: CELG, REGN, AMGN, ALNY, BLUE Also: BMY, LLY, LOXO
Read
Q2 Earnings Update: Bluebird Bio (BLUE) And Regeneron (REGN)
Article By: Rod Raynovich
Thursday, August 2, 2018 11:09 PM EDT
Regeneron Pharmaceuticals (REGN) soared 7% to $397 on earnings beat with adjusted EPS of $5.45. Bluebird Bio (BLUE) was up 0.79% to $156.60 despite losses and lagging revenue.
In this article: BLUE, REGN
Read
All Posts

PARTNER HEADLINES

Latest Tweets for $BLUE

No tweets yet!